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Summary
The idea of using platelet rich plasma (PRP) in medicine has been around
since the 1970s. It is only more recently that its use has been employed in
the area of musculoskeletal science. Platelet rich plasma in this area has
received much media attention being used by many celebrity sports
athletes for musculoskeletal injuries. Therefore it is important for the
musculoskeletal practitioner to be aware of the concepts surrounding its
use and application. In this article we cover what platelet rich plasma is,
how it is prepared and administered, its potential clinical application, and
what the current literature discusses in the various areas of
musculoskeletal science.
Introduction
Platelet rich plasma (PRP) is an autologous blood-
derived product that has an increased concen-
tration of platelets that are rich in growth factors,
and has the potential to enhance the healing of
tissue at the cellular level via the recruitment, pro-
liferation, and differentiation of cells involved in
tissue regeneration. There have been a number of
studies on the effect of PRP at the preclinical and
clinical level in musculoskeletal medicine, some
of which we will highlight in this article.
Methods
The basic science of PRP
Platelets are key components in haemostasis, and
stimulate the construction of new connective
tissue, and revascularization. Platelets are small,
regularly shaped, clear cells measuring between
2–3μm in diameter. They are derived from the
fragmentation of precursor megakaryocytes and
have a lifespan of 5–9 days. The physiological
range for platelets in humans is between 150 and
400 × 10
9 per litre. They normally circulate in the
blood and are involved in the formation of the
haemostatic plug.
1
A sample of blood will normally contain 93%
red blood cells, 6% platelets, and 1% white blood
cells.
2 In PRP the ratio of red blood cell to platelets
is reversed, thereby increasing factors that would
be more useful in healing. The exact ratio of red
and white blood cells to platelets in PRP is vari-
able depending on the way in which the PRP is
prepared.
There are three stages of platelet involvement
in the formation of the blood clot: activation,
secretion, and aggegration. Platelets in the body
are activated when they come in to contact with
von Willebrand factor, collagen (exposed endo-
thelium), or by the action of thrombin. Once acti-
vated, they secrete the contents of their alpha
and dense granules (Figure 1 and Table 1). The
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1alpha granules facilitate platelet adherence to the
exposed endothelium and the dense granules
lead to activation of the intrinsic coagulation
pathway. The growth factors released from these
granules facilitate the three stages of healing:
inﬂammation, proliferation, and remodelling by:
(1) initiating the clotting cascade (2) releasing his-
tamine and serotonin that increase capillary
Figure 1
Activation and secretion of platelets
Source: Getgood, A. Articular Cartilage Tissue Engineering. 2009. Cambridge University Library
Table 1
List of growth factors in Platelet Rich Plasma
3,4
Growth Factor Effect
PDGF Macrophage activation and angiogenesis
Fibroblast chemotaxis and proliferative activity
Enhances collagen synthesis
Enhances the proliferation of bone cells
TGF-Beta Enhances the proliferative activity of ﬁbroblasts
Stimulates biosynthesis of type I collagen and ﬁbronectin
Induces osteoclast formation and bone resorption
IGF-I Chemotactic for ﬁbroblasts and stimulates protein synthesis
Enhances bone formation by proliferation and differentiation of osteoblasts
PDEGF Promotes wound healing by stimulating the proliferation of keratinocyes and
dermal ﬁbroblasts
PDAF Induces vascularization by stimulating vascular endothelial cells
PF-4 Stimulates the initial reﬂux of neutrophils into wounds
A chemoattractant for ﬁbroblasts
A potent antiheparin agent
EGF Cellular proliferation
Differentation of epithelial cells
VEGF Angiogenesis
Migration and mitosis of endothelial cells
Creation of blood vessel lumen
Creates fenestrations
Chemotactic for macrophages and granulocytes
Vasodilation (indirectly by release of nitrous oxide)
PDGF =Platelet-Derived Growth Factor; TGF = Transforming Growth Factor; IGF= Insulin Growth Factor;
PDEGF = Platet-derived endothelial growth factor; PDAF= Platelet-derived angiogenesis factor; PF-4=
Platelet Factor 4; EGF = Endothelial Growth Factor; VEGF = Vascular Endothelial Growth Factor;
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2permeability of the area allowing inﬂammatory
cells greater access to the site and (3) encouraging
the migration of white blood cells. This leads to
cell proliferation while ﬁbroblasts begin to lay
the ground substance.
5 It is thought by creating a
concentrated formulation of the above factors in
PRP, an optimal environment could be created to
accelerate healing.
Formulation of PRP
PRP is prepared from blood which is treated to
concentrate the maximum amount of platelets.
Citrate is added to PRP to inhibit the coagulation
process, as the clot will contain the platelets. The
blood sample is then placed into a centrifuge
that will separate out the platelet rich plasma.
The next step is to release the associated growth
factors from the platelet. This can be done by
adding either: (1) Bovine thrombin to the platelet
rich plasma. This releases 70% of stored growth
factors within 10 minutes, and nearly 100%
within one hour.
5 A small amount of growth
factors will be released throughout the lifespan
of the platelet. (2) Calcium chloride to convert
autologous thrombin to prothrombin resulting in
platelets being trapped in a ﬁbrin matrix. As a
small amount of thrombin is formed, release of
growth factors is gradual over 7 days. (3) Use
type I collagen to activate platelet rich plasma.
Figure 2 is one example of a commercial process
to produce platelet rich plasma.
The various commercial preparation methods
for PRP do not produce the same product (Table 2
and Figure 3). Some are leukocyte rich, others are
leukocyte poor. The ideal preparation has yet to be
determined – there are papers on this which
suggest optimum values for PRP. There are a
variety of methods by which PRP could be
applied including: (1) By direct application, (2) By
single or multiple injections, (3) As a gel and (4)
In a collagen sponge. The most effective method
for each proposed use, has yet to be determined.
Current Clinical Applications
Bone
The standard approach to promoting bone repair
is to use bone grafting, a procedure that can
enable healing of both critical-sized defects and
refractory lesions. There are several areas where
there is a need for improvement; to reduce the
need for autograft harvest with its associated mor-
bidity, to improve the outcome seen when using
allogeneic bone, to reduce healing time thereby
reduce time to recovery and ideally to provide
off-the-shelf products with reproducible outcomes
that would replace the requirement for grafting.
Treatments that could enhance bone grafting or
be used to augment bone graft substitutes are
attractive and PRP offers this potential as it con-
tains a numberof growth factorsthat can stimulate
the proliferation and differentiation of cells of the
osteogenic lineage.
The ﬁrst use of PRP for bone repair was
described by Marx in 1998.
6 He reported a series
of 88 cases of mandibular continuity defects
treated with autograft bone of which half had
added PRP. Radiographs, produced at 2, 4 and 6
months, showed a signiﬁcant increase in maturity
and consolidation of the graft in patients treated
with PRP. These results were conﬁrmed by bone
biopsy at 6 months which showed a signiﬁcant
increase in trabecular bone density within the
PRP augmented graft. Subsequently, several pre-
clinical studies were reported investigating the
ability of PRP to improve healing with bone
graft
7 or with collagen and other graft substitute
materials
8 for various repair requirements. The
results of these studies have been equivocal with
some studies reporting improved healing with
PRP and others showing no effect. One of the
reasons for the discrepancy between studies has
been ascribed to differences in PRP activation pro-
tocols.
9 Interestingly, acomparison of the augmen-
tation of autologous graft with either PRP or bone
morphogenetic protein (BMP) for the repair of
mandibular defects in rats, showed improved
healing with BMP but not PRP.
10
Alongside this work there have been a number
of reports of clinical periodontal and maxillofacial
bone repair augmentations following on from the
work of Marx. Whilst a small number of these
showed a beneﬁcial effect of PRP, the majority
showed no effect.
11 Using a split-mouth technique
to control for PRP augmentation, Hanna et al.
showed improved clinical periodontal response
whilst Raghoebar et al. showed no effect.
12 One
meta analysis of the use of PRP in sinus bone
grafting indicated a small but signiﬁcant increase
in the odds ratio for increased bone formation but
no effect on subsequent implant survival,
13 whilst
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3another meta analysis of sinus lifting procedures
concluded that there was no signiﬁcant effect of
PRP augmentation.
14 There have been several
reports of clinical studies using human PRP in a
variety of orthopaedic procedures. A beneﬁcial
effect of PRP was described in distraction
osteogenesis, although this study may have been
biased by treatment self-selection.
15 In a random-
ized trial of augmented grafting in wedge osteot-
omy of the proximal tibia, Dallari et al. reported
improved osseointegration at follow-up times up
to 52 weeks and a signiﬁcant increase in bone for-
mation in a biopsy taken at 6 weeks.
16 PRP has
also been reported to promote healing in a series
of fracture non-unions.
17 However, a randomised
clinical trial of non-union healing showed only
68.3% healing with PRP compared to 86.7%
healing with BMP7
18 and a prospective random-
ized trial of the use of PRP in knee arthroplasty
found no signiﬁcant clinical effect.
19 A systematic
review of the use of PRP to promote bone healing
concluded that although PRP treatment was safe,
there was as yet no clinical evidence of beneﬁt.
20
The lack of unequivocal evidence for the effec-
tiveness of PRP augmentation of bone repair may
be due to a number of factors. The varied con-
ditions being treated and their site within the skel-
eton are probably, in part, responsible for the
variation in efﬁcacy. Reported studies have used
a variety of different methods for the production
of PRP and this will have an effect on the compo-
sition of the PRP produced. One key factor is the
number of platelets in the concentrate and
evidence has been put forward for an optimal
concentration. Other factors are the activation
method used and the interaction of the platelets
and released growth factors with the graft material
used. The timing of analysis may also be impor-
tant; in a study of PRP augmentation of the
repair of frontal skull defects, changes were seen
in the production of bone matrix proteins and
bone regeneration at early time points but no long-
term effect on bone formation.
21 Further prospec-
tive randomized clinical trials, with sufﬁcient
patients to provide statistical power, are required
Table 2
A sample of various commercially available
System,
company
Whole Blood
Volume (ml)
Activator Centrifuge
Time (min)
Volume of
PRP (ml)
Leukocytes
Cascade, PRFM 18 Calcium Chloride 6 7.5 No
Harvest,
SmartPrep 2
20–120 Bovine thrombin 14 3–20 Yes
Biomet, GPS III 27–110 Autologous thrombin
with calcium chloride
15 3–12 Yes
Figure 2
SmartPrep PRP set up
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4for recommendations regarding the use of PRP to
augment bone repair to be given and these have
been proposed for fracture repair.
22
Tendon and ligaments
Tendon and ligaments heal more slowly than most
tissues due to poor vascular supply.
23 This can
result in new tendon tissue that does not have the
same structural and functional properties as the
original tissue when healed and leads to scar
tissue. One possible explanation is that the poor
blood supply results in a lack of adequate growth
factors being delivered to the site of injury.
24 Given,
then, that there are problems with tendon and
ligament healing, it is possible that PRP , as a good
source of growth factors, may enhance healing.
Certain rotator cuff tears (including massive
tears and chronic injuries) have a high failure rate
of repair. There have been several randomized con-
trolled trials investigating the effects of PRP in
rotator cuff repair, and the results have been disap-
pointing. For example, one randomized controlled
trial
25 that examined the effect of PRP on the
efﬁcacy of arthroscopic rotator cuff repair, found
no statistically signiﬁcant difference in clinical or
imaging outcomes compared to the placebo group.
PRP has also been explored in anterior cruciate
ligament reconstruction. Two randomized con-
trolled trials
26,27 showed no statistically signiﬁcant
difference in bone ﬁlling of the bone tunnels in
ACL reconstructions as visualized on MRI,
though one of these found an improvement in
the clinical score. Another randomized controlled
trial
28 of 108 patients, showed at 6 months that
PRP had an enhancing effect on the maturation
of the graft as visualized by MRI.
The effect of PRP on Achilles tendinopathy
treatment has also been investigated. In this con-
dition it appears that the outcome may depend
on whether the injury is acute or chronic. A
recent randomized controlled trial by de Vos et al.
showed at 24 weeks,
29 and 1-year follow-up,
30
that PRP had no statistically signiﬁcant beneﬁt in
clinical scoring outcome or ultrasound ﬁndings
in chronic Achilles tendinopathy. However, in
PRP treatment of acute Achilles tendon damage,
studies have shown a quicker recovery time
31
and a better Achilles tendon rupture score.
32
Otherareas explored include lateral epicondyli-
tis, where it has been shown at two years that
injecting PRP improved healing as compared to
injecting corticosteroids at two
33 years post-
treatment in a 100 patient trial. The use of PRP n
patellar tendinopathy appears to be favourable.
34
However, in general, very few randomized con-
trolled trials have been conducted on small
cohorts of patients in each speciﬁc area of clinical
tendinopathy. Further studies must be conducted
before a speciﬁc conclusion can be made.
Muscle
As with the other tissues already discussed, it can
be hypothesized that the use of PRP will accelerate
muscle healing. At the current time, little evidence
exists to support this hypothesis. Indeed, some
researchers have suggested that PRP may actually
lead to unwanted ﬁbrotic healing in muscle.
35
Figure 3
Two-step centrifugation procedure – Production of leukocyte rich/
poor PRP (Taken from Dohan Ehrenfest, Rasmusson et al. 2009)
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5In surgically created tibialis anterior muscle
defects in rats, PRP injections led to a quicker
time to recovery than in platelet poor plasma or
sham treated animals.
36 Cugat et al. conducted a
cohort study of 14 professional athletes with
acute muscle injuries who were treated with
ultrasound-guidance injections of PRP. The
patients showed a quick return to play and
enhanced healing in tears assessed ultrasonogra-
phically. These ﬁndings agree with Sanchez
et al.
37 who reported a similar study in 20 athletes
who found that patients recovered in half of the
expected time. These results are not from random-
ized, well controlled trials involving large
numbers of patients but are, nevertheless, suppor-
tive of the idea that PRP could play a key role in
muscle healing. A numberof prospective random-
ized trials are currently being conducted in this
area and will hopefully help to formulate future
treatment recommendations.
38
Cartilage
Articular cartilage lacks the vascularization and
inﬂammatory processes that enable effective
repair. Endogenous chondrocytes can synthesize
ﬁbrous repair tissue but not sufﬁciently to ﬁll
even small defects with a cartilage-like matrix.
39
PRP has been promoted as a potential agent for
therapeutic repair of cartilage
40 due to the range of
beneﬁcial growth factors released on activation.
41
Of these it is likely that PDGF, TGF and FGF
exert the greatest beneﬁcial effects on cartilage
and chondrocytes. Some anti-inﬂammatory prop-
erties of PRP have also been demonstrated,
42 but
the variable nature of PRP has led to conﬂicting
data making an overall assessment of its worth in
tissue repair difﬁcult. Donor variability, PRP prep-
aration method, scaffold type, cell origin and
culture conditions have all been shown to alter
the levels of growth factor release orcell responses.
Many authors agree that PRP increases chon-
drocytes proliferation, but there is still consider-
able debate as to the inﬂuence of PRP on
chondrogenic differentiation and cartilage
matrix accumulation. Akeda et al.
43 demon-
strated that porcine chondrocytes entrapped in
alginate, produced the highest proteoglycan
and collagen synthesis, and the majority of the
collagen expressed was type II collagen when
treated with PRP compared to chondrocytes cul-
tured with PPP or FCS. Spreaﬁco et al.
44 cultured
human chondrocytes in a PRP/ﬁbrin gel and
demonstrated reduced de-differentiation and
increased matrix synthesis compared to cells
treated with FCS or PPP. However, conﬂicting
data was reported by Kaps et al.
45 (bovine chon-
drocytes), Gaissmair et al.
46 (human chondro-
cytes) and Drengk et al.
47 (sheep chondrocytes).
These studies suggested that PRP enhanced de-
differentiation of chondrocytes and did not con-
tribute to cartilage matrix synthesis in in vitro
3D culture. However, it should be emphasized
that most of these studies use different sources
and preparation methods for the cells, different
expansion conditions and supplements for
expanding the cells, and different methods of
PRP preparation. One key factor affecting PRP
potency is the type of activation that it undergoes
during preparation or when incorporated into
the experiment. Thrombin activation can elimin-
ate the chondrogenic and osteoinductive poten-
tial of PRP.
48 Two other studies
49,50 achieved
chondrogenic induction of BMSCs by using
freeze–thaw cycles to activate PRP, whilst
Getgood et al.
51 demonstrated enhanced acti-
vation of PRP when it was combined with a col-
lagen/glycosaminoglycan scaffold for
osteochondral repair.
PRP also has potential for articular cartilage
repair by direct application into the damaged joint;
either as a liquid, gel or entrapped in a delivery
device. Sampson et al
52 carried out a single-centre,
uncontrolled, prospective preliminary study on 14
patients with primary and secondary knee osteoar-
thritis. The patients received three PRP injections
in the affected knee at 4-wk intervals. Although
designed as a preliminary safety study for PRP, the
results demonstrated signiﬁcant and almost linear
improvements in knee injury and osteoarthritis
outcome scores, including pain and symptom relief.
Kon et al.
53 carried out a study on 100 patients
(115 knees) treated with PRP which was evaluated
by IKDC- and EQ-V AS scores. The study demon-
strated that PRP treatment is safe, reduces pain
and improves knee function, especially in
younger patients. However, at the 24-month
follow-up, the outcome (IKDC score) worsened
from 67% to 59% of normal or nearly normal
knees between the 12- and 24-month evalu-
ations.
54 A study by the same group using an
ovine model concluded that PRP had a negative
effect on osteochondral repair when compared to
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55 However, Milano et al.
56 demon-
strated positive effects of PRP in an ovine micro
fracture model with PRP gel being more effective
than a PRP injection. The beneﬁcial effects of
PRP on cartilage repair have also been reported
in a rabbit model of osteoarthritis
57 and in a
rabbit osteochondral defect model.
58
In conclusion, PRP is showing promise in the
ﬁeld of cartilage repair but the adoption of stan-
dardized preparation and usage protocols will be
required for future studies to enable meaningful
statistical data to be generated.
Meniscus
There are few studies speciﬁcally targeting menisci
withPRP.However,isolatedmeniscalcellsgrownin
vitrohavebeendemonstratedtorespondtoindivid-
ual growth factors present in PRP including TGF,
IGF and PDGF.
59 Ishida and co-workers
60 demon-
strated an in vitro reaction to PRP using cultured
meniscal ﬁbroblasts and observed improved tissue
inﬁlling in gelatine/PRP inserts 12 weeks post-
operatively in a rabbit meniscal defect. However,
Zellner and co-workers,
61 using a double centrifu-
gation PRP preparation method, found no beneﬁt
to adding their PRP to a hyaluronan/collagen
plug in a rabbit meniscal defect by comparison to
the following groups: empty defects, plugs with
bone marrow aspirate, MSC with and without pre-
chondrogenic in vitro treatment. Fibrin clots, pro-
duced by agitating blood with glass beads until a
clot formed, were used by Arzonscky and co-
workers.
62 The clots were rinsed of excess red
blood cells using sterile saline and used to pack
2 mm meniscal defects in dogs. Opposite knees
were operated in the same way but with extensive
saline rinsing before ﬁnishing. The ﬁbrin packed
defects ﬁlled with ﬁbrocartilagenous-like tissue at
six months, although the tissue was histologically
distinct to the mature tissue.
Althoughmenisciarenotessentialforjointfunc-
tion, meniscal resection leads to long-term destabi-
lization and degradation of the articular surfaces.
63
AutologousbloodproductssuchasPRP,Fibrinand
blood provide an increase of factors demonstrated
to inﬂuence meniscal cells and may be one initial,
simple, route to improve healing. However, the
studies presented here are limited in the PRP
types used, and the numbers of patient studies
speciﬁcally investigating PRP on the menisci
remains relatively low at the current time.
Discussion
It is difﬁcult to make a general conclusion on the
use of platelet-rich plasma in musculoskeletal
medicine. Commercial preparations of platelet-
rich plasma vary in terms of growth factors, acti-
vation, and platelet concentration. This is com-
pounded by the fact that clinical investigations
of platelet-rich plasma differ in application
methods, timing, and volume of platelet-rich
plasma used. Many of the published studies are
not randomized controlled trials, and may not be
at the appropriate statistical power to identify
whether the treatment works or not. We are reluc-
tant to dismiss PRP, as its clinical beneﬁts could be
varied bya numberof factors in its production and
application. PRP also offers many beneﬁts such as
being safe, easy to extract, relatively simple and
short time to process, offering multiple growth
factorsatarelativelyinexpensivecost,ascompared
toobtainingindividualgrowthfactorsorevenstem
cells. It is for these reasons, and becausewe believe
that the PRP potential has yet to be fully explored,
that we would consider further investigation of
PRP be warranted. We suggest as others have
done that scientiﬁc studies need to be conducted
to determine the optimal: (1) process method (2)
volume (3) delivery (4) timing (5) indication (6)
single vs series of injections (7) and rehabilitation
protocol – for PRP.
Interventions in musculoskeletal medicine aim
to achieve predictable, rapid tissue repair, and
enhance tissue repair for the quickest recovery
time. PRP may have the potential to bring this
about, however a number of further high-level
investigations need to be conducted before a con-
clusion can be made on PRP.
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